Glenmark receives US FDA approval for generic psoriatic arthritis drug.
Introduction:
Recently, Glenmark Pharma made headlines when selling Nirma 75% of its subsidiary Glenmark Lifesciences for Rs. 5651 crore.
The generic form of Otezla 1 Tablets, 10 mg, 20 mg, and 30 mg, manufactured by Amgen Inc., has been given final approval by the United States Food & Drug Administration (U.S. FDA), according to Indian pharmaceutical giant Glenmark Pharmaceuticals Ltd.
The market for Otezla Tablets, 10 mg, 20 mg, and 30 mg generated annual sales of over $3.7 billion, according to IQVIA sales statistics for the 12-month period ending August 2023.
In the first quarter of FY 24, the Mumbai-based pharmaceutical company’s net profit fell by 22% from the previous year to Rs 150 crore. Glenmark Pharma recently made headlines after selling Nirma for Rs 5,651 crore 75% of its subsidiary Glenmark Lifesciences.
At 9.35 am on the NSE, the company’s shares are slightly higher at Rs 802.80.
The post Glenmark Receives US. appeared first on ASWGROUPINDIA.
The post Glenmark receives US. appeared first on ASWGROUPINDIA.
